PROVIDER RESOURCES & RESEARCH
​READ
Comprehensive Overview of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Gastroenteropancreatic Neuroendocrine Tumors
Vijayvergia et al., Gastroenterology (2025)
https://doi.org/10.1053/j.gastro.2025.07.004
​
This high-quality review article provides an up-to-date, clinically relevant overview of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It summarizes current understanding of epidemiology, advances in diagnostic imaging—including the expanding role of SSTR-PET—and evidence-based management strategies across surgery, somatostatin analogs, PRRT, and emerging targeted therapies (e.g., mTOR and anti-VEGF inhibitors).
​
An excellent reference for clinicians seeking a concise, authoritative update on the fundamentals and evolving landscape of NET care.
Paradigm Shift in Neuroendocrine Neoplasm Classification
Neuroendocrine neoplasm classification: The missing piece of the puzzle
Grewal et al., Cell Reports Medicine (2025)
https://doi.org/10.1016/j.medj.2025.100897
​
Current NET classifications mostly rely on where the tumor started (site of origin), how fast it’s growing (Ki-67), and how differentiated the cells are. This article by Grewal et al. highlights how adding molecular information—unique genetic or biological “fingerprints” of a tumor—can provide important clues about prognosis and help guide more personalized treatment options and clinical trial opportunities. The authors also show that combining advanced imaging with blood-based molecular tests can offer a clearer, more dynamic picture of how the disease is behaving.
Why this matters: These advances may help patients and care teams make more informed decisions, detect changes earlier, and move toward more individualized, precision-based NET care.
​​
Integrating Patient Priorities Into NET Treatment Sequencing
Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review
Lewis et al., JCO Oncology Practice (2025)
https://ascopubs.org/doi/10.1200/OP-25-00474
​
Co-authored in partnership with patient advocates, including our Director of Programs & Outreach, Lisa Yen, this review underscores the critical role of the patient perspective in treatment planning for gastroenteropancreatic NETs. It highlights how treatment sequencing—particularly the use and timing of radioligand therapy (RLT)—can meaningfully influence both clinical outcomes and patient quality of life. The article emphasizes the importance of clear communication, transparency around rationale, and shared decision-making so that treatment plans reflect not only evidence-based best practices but also patient goals, preferences, and lived experience.
​
TAKE-HOME MESSAGE FOR HCPs: Patients and caregivers bring essential insight into how treatments impact their daily lives, priorities, and tolerance for side effects. Inviting and integrating their perspectives—early and often—supports more individualized care, strengthens trust, and ensures that treatment sequencing aligns with what matters most to the patient, not just the disease biology.